Clinico-genomic characterization of patients with metastatic urothelial carcinoma in real-world practice identifies a novel bladder immune performance index (BIPI)
B Szabados, M Ponz-Sarvisé, R Machado… - Clinical Cancer …, 2022 - AACR
Purpose: This retrospective analysis of the largest available clinico-genomic database used
de-identified patient-level electronic health record–derived real-world data (RWD) combined …
de-identified patient-level electronic health record–derived real-world data (RWD) combined …
Clinico-genomic characterization of patients with metastatic urothelial carcinoma in real-world practice and development of a novel bladder immune prognostic index …
B Szabados, M Ponz-Sarvise, R Machado, D Saldana… - 2022 - ascopubs.org
548 Background: Real-world data (RWD) linking clinical outcomes with comprehensive
genomic profiling (CGP) may enable identification of biomarkers to guide treatment selection …
genomic profiling (CGP) may enable identification of biomarkers to guide treatment selection …
Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma
RP Graf, V Fisher, RSP Huang, O Hamdani… - JCO Precision …, 2022 - ascopubs.org
PURPOSE In real-world settings, patients with metastatic urothelial carcinoma (mUC) are
often more frail than clinical trials, underscoring an unmet need to identify patients who …
often more frail than clinical trials, underscoring an unmet need to identify patients who …
Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real …
S Gupta, RSP Huang, J Stanke, O Hamdani, O Gjoerup… - 2022 - ascopubs.org
547 Background: There is an unmet need to identify metastatic urothelial carcinoma (mUC)
patients who might be spared chemotherapy in 1st line. Anti-PD-(L) 1 immune checkpoint …
patients who might be spared chemotherapy in 1st line. Anti-PD-(L) 1 immune checkpoint …
[HTML][HTML] Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
Abstract Urothelial Cancer-Genomic Analysis to Improve Patient Outcomes and Research
(NCT02643043), UC-GENOME, is a genomic analysis and biospecimen repository study in …
(NCT02643043), UC-GENOME, is a genomic analysis and biospecimen repository study in …
[HTML][HTML] RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre, A Brugarolas - BMC cancer, 2021 - Springer
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
[HTML][HTML] Identification of an immune-related risk signature correlates with immunophenotype and predicts anti-PD-L1 efficacy of urothelial cancer
P Li, S Hao, Y Ye, J Wei, Y Tang, L Tan… - Frontiers in Cell and …, 2021 - frontiersin.org
Immune checkpoint inhibitor (ICI) treatment has been used to treat advanced urothelial
cancer. Molecular markers might improve risk stratification and prediction of ICI benefit for …
cancer. Molecular markers might improve risk stratification and prediction of ICI benefit for …
[HTML][HTML] Prognosis stratification and personalized treatment in bladder cancer through a robust immune gene pair‐based signature
To the Editor: Numerous prognostic signatures to bladder cancer (BCa) have been reported,
but many of them limited to either nonmuscle-invasive (NMIBC) or muscle-invasive BCa …
but many of them limited to either nonmuscle-invasive (NMIBC) or muscle-invasive BCa …
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and …
SW Baek, SH Leem - International Journal of Molecular Sciences, 2024 - mdpi.com
Approximately 75% of bladder cancer cases originate as non-muscle-invasive bladder
cancer (NMIBC). Despite initial diagnosis, NMIBC commonly recurs, with up to 45 …
cancer (NMIBC). Despite initial diagnosis, NMIBC commonly recurs, with up to 45 …
Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L) 1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC) …
WY Kim, TL Rose, F Roghmann, M Eckstein, J Jarczyk… - 2020 - ascopubs.org
493 Background: The tumor microenvironment in UC harboring FGFR gene alterations is
characterized by decreased T-cell infiltration and low immune marker expression, potentially …
characterized by decreased T-cell infiltration and low immune marker expression, potentially …
相关搜索
- urothelial carcinoma checkpoint inhibitor
- metastatic urothelial cancer
- chemotherapy benefit checkpoint inhibitor
- predictive biomarker checkpoint inhibitor
- checkpoint inhibitors bacillus calmette
- genomic biomarkers bladder cancer
- personalized treatment bladder cancer
- urothelial cancer risk signature
- prognosis stratification bladder cancer
- patients pts pooled analysis
- treatment outcomes pooled analysis
- predictive value pooled analysis
- checkpoint inhibitors bladder cancer
- urothelial bladder cancer
- bacillus calmette bladder cancer